William P Martin1, Chloe Conroy2, Serika D Naicker3, Sarah Cormican3,4, Tomás P Griffin3,5, Md Nahidul Islam3, Eibhlin M McCole6, Ivan McConnell7, John Lamont7, Peter FitzGerald7, John P Ferguson8, Ciarán Richardson6, Susan E Logue3, Matthew D Griffin3,4. 1. Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland. 2. School of Medicine, University College Dublin, Dublin, Ireland. 3. Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, School of Medicine, National University of Ireland Galway, Galway, Ireland. 4. Nephrology Services, Galway University Hospitals, Saolta University Health Care Group, Galway, Ireland. 5. Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Saolta University Health Care Group, Galway, Ireland. 6. Randox Teoranta, Dungloe, Donegal, Ireland. 7. Randox Laboratories Limited, Crumlin, Antrim, Northern Ireland. 8. Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland.
Abstract
BACKGROUND: We investigated the predictive value of 11 serum biomarkers for renal and mortality end points in people with CKD. METHODS: Adults with CKD (n=139) were enrolled from outpatient clinics between February 2014 and November 2016. Biomarker quantification was performed using two multiplex arrays on a clinical-grade analyzer. Relationships between biomarkers and renal and mortality end points were investigated by random forests and Cox proportional hazards regression. RESULTS: The cohort was 56% male. The mean age was 63 years and median (IQR) CKD-EPI eGFR was 33 (24-51) ml/min per BSA. A total of 56 (40%) people developed a composite end point defined as ≥40% decline in eGFR, doubling of serum creatinine, RRT, or death over median (IQR) follow-up of 5.4 (4.7-5.7) years. Prediction of the composite end point was better with random forests trained on serum biomarkers compared with clinical variables (area under the curve of 0.81 versus 0.78). The predictive performance of biomarkers was further enhanced when considered alongside clinical variables (area under the curve of 0.83 versus 0.81 for biomarkers alone). Patients (n=27, 19%) with high soluble TNF receptor-1 (≥3 ng/ml) and neutrophil gelatinase-associated lipocalin (≥156 ng/ml), coupled with low complement 3a des-arginine (<2368 ng/ml), almost universally (96%) developed the composite renal and mortality end point. C-reactive protein (adjusted hazard ratio, 1.4; 95% CI, 1.1 to 1.8), neutrophil gelatinase-associated lipocalin (adjusted hazard ratio, 2.8; 95% CI, 1.3 to 6.1) and complement 3a desarginine (adjusted hazard ratio, 0.6; 95% CI, 0.4 to 0.96) independently predicted time to the composite end point. CONCLUSIONS: Outpatients with the triad of high soluble TNF receptor-1 and neutrophil gelatinase-associated lipocalin coupled with low complement 3a des-arginine had high adverse event rates over 5-year follow-up. Incorporation of serum biomarkers alongside clinical variables improved prediction of CKD progression and mortality. Our findings require confirmation in larger, more diverse patient cohorts.
BACKGROUND: We investigated the predictive value of 11 serum biomarkers for renal and mortality end points in people with CKD. METHODS: Adults with CKD (n=139) were enrolled from outpatient clinics between February 2014 and November 2016. Biomarker quantification was performed using two multiplex arrays on a clinical-grade analyzer. Relationships between biomarkers and renal and mortality end points were investigated by random forests and Cox proportional hazards regression. RESULTS: The cohort was 56% male. The mean age was 63 years and median (IQR) CKD-EPI eGFR was 33 (24-51) ml/min per BSA. A total of 56 (40%) people developed a composite end point defined as ≥40% decline in eGFR, doubling of serum creatinine, RRT, or death over median (IQR) follow-up of 5.4 (4.7-5.7) years. Prediction of the composite end point was better with random forests trained on serum biomarkers compared with clinical variables (area under the curve of 0.81 versus 0.78). The predictive performance of biomarkers was further enhanced when considered alongside clinical variables (area under the curve of 0.83 versus 0.81 for biomarkers alone). Patients (n=27, 19%) with high soluble TNF receptor-1 (≥3 ng/ml) and neutrophil gelatinase-associated lipocalin (≥156 ng/ml), coupled with low complement 3a des-arginine (<2368 ng/ml), almost universally (96%) developed the composite renal and mortality end point. C-reactive protein (adjusted hazard ratio, 1.4; 95% CI, 1.1 to 1.8), neutrophil gelatinase-associated lipocalin (adjusted hazard ratio, 2.8; 95% CI, 1.3 to 6.1) and complement 3a desarginine (adjusted hazard ratio, 0.6; 95% CI, 0.4 to 0.96) independently predicted time to the composite end point. CONCLUSIONS: Outpatients with the triad of high soluble TNF receptor-1 and neutrophil gelatinase-associated lipocalin coupled with low complement 3a des-arginine had high adverse event rates over 5-year follow-up. Incorporation of serum biomarkers alongside clinical variables improved prediction of CKD progression and mortality. Our findings require confirmation in larger, more diverse patient cohorts.
Authors: Robert G Weaver; Matthew T James; Pietro Ravani; Colin G W Weaver; Edmund J Lamb; Marcello Tonelli; Braden J Manns; Robert R Quinn; Min Jun; Brenda R Hemmelgarn Journal: J Am Soc Nephrol Date: 2020-02-05 Impact factor: 10.121
Authors: Karolina Kędzierska; Krzysztof Sindrewicz; Katarzyna Sporniak-Tutak; Edyta Gołembiewska; Labib Zair; Jerzy Sieńko; Małgorzata Stańczyk-Dunaj; Irena Baranowska-Bosiacka; Kazimierz Ciechanowski Journal: Ann Transplant Date: 2016-03-03 Impact factor: 1.530
Authors: Yun Jung Oh; Jung Nam An; Clara Tammy Kim; Seung Hee Yang; Hajeong Lee; Dong Ki Kim; Kwon Wook Joo; Jin Ho Paik; Shin-Wook Kang; Jung Tak Park; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: William P Martin; Colm Tuohy; Alison Doody; Sabrina Jackson; Ronan J Canavan; David Slattery; Patrick J Twomey; Malachi J McKenna; Carel W le Roux; Neil G Docherty Journal: Sci Rep Date: 2020-09-09 Impact factor: 4.379
Authors: Anand Srivastava; Insa M Schmidt; Ragnar Palsson; Astrid Weins; Joseph V Bonventre; Venkata Sabbisetti; Isaac E Stillman; Helmut G Rennke; Sushrut S Waikar Journal: Kidney Int Rep Date: 2021-01-06